“Vitality shows in not only the ability to persist but the ability to start over.”
— F. Scott Fitzgerald
A favorite quote from the Jazz Age king that nicely captures life as a biotech entrepreneur.
This blog was written by Kevin Pojasek, Founder and acting CEO of Quartet Medicine, as part of the “From the Trenches” feature of LifeSciVC.
Are you ready for the circus? Next week’s JPM Healthcare Conference is getting ready to kickoff, and much of the healthcare industry is feverishly preparing their materials for the mayhem.
Given the biopharma industry pipeline’s exciting clinical progress, a record-breaking year of FDA approvals, a buoyant stock market, and 2014’s chart-topping biotech IPO volume – it’s bound to be a positive and optimistic kickoff to the year.
Checkpoint inhibitors, designed to help the immune system better identify and attack cancer, have become the consensus next big things in oncology. But startup Surface Oncology is looking beyond their transformative promise with eyes on the next generation of immunotherapies, chasing some newly identified targets and raising $35 million to get rolling.
Another day, another announcement about great data from immuno-oncology. It’s clearly one of the hottest fields in biopharma today, and has been for a few years. Read more.
Intellia Therapeutics, a leader in the development of therapeutic products using CRISPR/Cas9 technology for gene editing and repair, today announced a five-year research and development collaboration with Novartis to accelerate the ex vivo development of new CRISPR/Cas9-based therapies using chimeric antigen receptor T cells (CARTs) and hematopoetic stem cells (HSCs). This collaboration comes only three months after Intellia was launched by Atlas Venture and Caribou Biosciences, providing an important validation of Intellia’s team and capabilities.